Is erdafitinib currently on the market in China?

Erdafitinib (Erdafitinib) is a new targeted therapy drug mainly used to treat patients with locally advanced or metastatic urothelial cancer (UC; bladder cancer ) who carry susceptible FGFR3 gene mutations. On January 13, 2025, the State Food and Drug Administration issued the latest announcement, announcing that Erdafitinib tablets applied by Johnson & Johnson Pharmaceuticals Co., Ltd. were approved for marketing in China. This marks the entry of erdafitinib into the Chinese market and becomes a new option for the treatment of urothelial cancer.

According to public information, the approved indication of erdafitinib tablets in China is the treatment of adult patients carrying FGFR3 gene mutations, especially for patients with surgically unresectable locally advanced or metastatic urothelial cancer who have received at least first-line anti-PD-1 or anti-PD-L1-containing therapy and have disease progression. Compared with traditional chemotherapy methods, erdafitinib, as a targeted drug, inhibits the growth of tumor cells by inhibiting the fibroblast growth factor receptor (FGFR) signaling pathway. It has a more precise therapeutic effect and can effectively delay the progression of tumors.

In clinical application, the efficacy of erdafitinib has received widespread attention. By selectively inhibiting the activity of FGFR3 mutations, it can effectively inhibit the proliferation of tumor cells, especially when PD-1 or PD-L1 immunotherapy fails, bringing new treatment hope to patients. Targeted treatment strategies targeting FGFR gene mutations have become an important breakthrough in the treatment of urothelial cancer.

Currently, the launch of erdafitinib in the Chinese market provides patients with new treatment options. However, due to its special indications and targeting effects, patients need to undergo genetic testing to confirm whether they are suitable for this drug before use. It is worth noting that although erdafitinib has been approved for marketing in China, it is not included in the scope of medical insurance reimbursement, so patients still need to bear higher treatment costs.

References：https://www.balversa.com/